Existing drugs offer new treatment options for high-risk childhood leukemia subtype
Scientists have identified new genetic alterations underlying a high-risk subtype of the most common childhood cancer that could be effectively targeted with existing leukemia therapies.
The study focused on a subtype of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-like ALL (Ph-like ALL). This subgroup accounts for as much as 15 percent of childhood ALL that is associated with a high risk of relapse and a poor outcome. The genetic changes driving the disease were previously unknown for about half of all patients with Ph-like ALL. The work identified new alterations in genes that regulate how cells grow and proliferate. St. Jude Children's Research Hospital investigators led the research, which appears in the online edition of the journal Cancer Cell.
Investigators also showed that the leukemia cells were sensitive to several targeted therapeutic agents, imatinib and dasatinib, which are already being used against other leukemias, but not this subtype. The findings suggest patients with Ph-like ALL may benefit from the addition of these drugs to current chemotherapy regimens.
"One of the next steps will be to continue work on laboratory tests to rapidly identify patients whose cancer cells carry these alterations and to develop clinical trials to test targeted therapies," said Charles Mullighan, M.D., Ph.D., an associate member of the St. Jude Department of Pathology, and a corresponding author of the study.
The study involved sequencing the RNA of cancer cells from 15 patients with Ph-like ALL and whole genome sequencing of two of those patients. Whole genome sequencing involves deciphering the DNA molecule, which contains the complete set of instructions for building and maintaining life. Cells use RNA to translate DNA's instructions into proteins. Sequencing RNA provides a snapshot of gene activity in a cell.
The work was part of the National Cancer Institute's Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative, which aims to use genomics to identify therapeutic targets and spur development of more effective treatments for childhood cancer. NCI is part of the National Institutes of Health. The collaboration included investigators from St. Jude, the Children's Oncology Group and the British Columbia Genome Sciences Center.
"This work is another example of how a detailed analysis of the genetic changes present in cancer cells can identify the changes that are critical for cancer cells to escape normal growth controls and allow them to resist standard chemotherapy treatments, but also serve as an Achilles' heel that can be attacked by drugs targeted at these genetic changes. It's also important to recognize that work like this is only possible because patients with ALL and their parents agreed to participate in clinical trials and linked studies about the genetics of cancer," said Stephen Hunger, M.D., a professor of pediatrics at the University of Colorado, chairman of the Children's Oncology Group ALL Committee and a corresponding author of the study.
ALL is the most common childhood cancer. While approximately 90 percent of newly diagnosed ALL patients are cured with current treatments, only 63 percent of children with Ph-like ALL are alive and cancer-free after five years.
Ph-like ALL is named after a chromosomal rearrangement known as the Philadelphia chromosome, which is associated with another subtype of ALL. The two subtypes share similar gene expression profiles, but patients with Ph-like ALL lack the fusion of the BCR and ABL1 genes that is a hallmark of Philadelphia-positive ALL.
To determine the genetic basis of Ph-like ALL, investigators performed transcriptome and whole genome sequencing on cancer cells from young patients with Ph-like ALL. Researchers found the 15 patients harbored genetic alterations, including mutations, chromosomal rearrangements or structural variations, which disrupted tyrosine kinase or cytokine receptor signaling. Kinases are enzymes that function as on-off switches in cells. Cytokine receptors regulate how cells respond to growth factors known as cytokines.
Researchers also found the leukemia cells carried additional mutations or deletions affecting IKZF1 and other genes involved in normal B cell development. "This supports the notion that many subtypes of ALL have at least two key pathways disrupted. One is a block in maturation of immature B cells and the other drives proliferation of those cells," Mullighan said.
When investigators screened another 436 young patients with high-risk B-cell ALL, they found some patients with Philadelphia-like ALL carried the same alterations. Those changes included the fusion of a gene named EBF1 to the tyrosine kinase gene PDGFRB. This study is the first to link the EBF1-PDGFRB fusion to cancer. Other fusions associated with ALL for the first time involved the genes STRN3-JAK2 and RANBP2-ABL1.
Researchers also showed that expression of EBF1-PDGFRB freed white blood cells from normal controls and allowed them to proliferate in the absence of growth factor. The addition of the tyrosine kinase inhibitors imatinib and dasatinib slowed proliferation and induced cell death.
When human Ph-like ALL cells expressing the NUP214-ABL1 rearrangement were transplanted into mice, the animals responded to treatment with dasatinib. Another mouse model of human Ph-like ALL that included a BCR-JAK2 fusion showed a dramatic reduction of leukemia cells following treatment with the JAK2 inhibitor, ruxolitinib. The drug is approved for use against other blood disorders with mutations in JAK2, a protein involved in cytokine signaling. Together these results suggest that although a wide range of alterations exist in Ph-like ALL, they converge on similar pathways that can be targeted with currently available ABL1 or JAK2 inhibitors.
"Although much work remains to be done, these results suggest most patients with this cancer subtype may respond to treatment with currently available tyrosine kinase inhibitors," said Kathryn Roberts, Ph.D., a St. Jude postdoctoral fellow. She and Ryan Morin, Ph.D., of the BC Cancer Agency, Vancouver, Canada, are the study's first authors.
Journal reference: Cancer Cell
Provided by St. Jude Children's Research Hospital
- Cancer sequencing project identifies potential approaches to combat aggressive leukemia Jan 11, 2012 | not rated yet | 0
- New chromosomal abnormality identified in leukemia associated with Down syndrome Oct 18, 2009 | not rated yet | 0
- Genetics of imatinib resistance in acute lymphoblastic leukemia Aug 30, 2007 | not rated yet | 0
- When leukemia returns, gene that mediates response to key drug often mutated Mar 09, 2011 | not rated yet | 0
- Gene sequencing project identifies potential drug targets in common childhood brain tumor Jun 20, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
How can there be villous adenoma in colon, if there are no villi there
10 hours ago As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
- More from Physics Forums - Medical Sciences
More news stories
(HealthDay)—The American Cancer Society, which is celebrating on Wednesday a century of fighting a disease once viewed as a death sentence, is making a pledge to put itself out of business.
Cancer 47 minutes ago | not rated yet | 0
National Lung Screening Trial (NLST) investigators also conclude that the 20 percent reduction in lung cancer mortality with low-dose computed tomography (LDCT) versus chest X-ray (CXR) screening previously reported in the ...
Cancer 1 hour ago | not rated yet | 0
Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage ...
Cancer 4 hours ago | not rated yet | 0 |
When turned on, the gene p53 turns off cancer. However, when existing drugs boost p53, only a few tumors die – the rest resist the challenge. A study published in the journal Cell Reports shows how: tumors that live even i ...
Cancer 4 hours ago | not rated yet | 0 |
Study leader, Professor John Mathews from the University of Melbourne said this small increase in cancer risk must be weighed against the undoubted benefits from CT scans in diagnosing and monitoring disease.
Cancer 8 hours ago | not rated yet | 0
(HealthDay)—Implementation of systematic monitoring for medication adherence will allow for identification of barriers to adherence and tailoring of interventions, according to a viewpoint piece published ...
47 minutes ago | not rated yet | 0
(AP)—A federal panel of medical experts says that an experimental insomnia drug from Merck & Co Inc. appears safe and effective, despite evidence from company trials that the pill can cause daytime sleepiness and difficulty ...
7 minutes ago | not rated yet | 0
(HealthDay)—Migraines and depression can each cause a great deal of suffering, but new research indicates the combination of the two may be linked to something else entirely—a smaller brain.
1 hour ago | 5 / 5 (1) | 0 |
Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.
2 hours ago | not rated yet | 1 |
As the world prepares for what may be the next pandemic strain of influenza virus, in the H7N9 bird flu, a new UC Irvine study reveals that the 2009 H1N1 swine flu pandemic was deadliest for people under the age of 65, while ...
1 hour ago | not rated yet | 0